Is the Foracort inhaler (budesonide/formoterol) comparable to Dulera (mometasone/formoterol)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Foracort and Dulera Are Comparable ICS/LABA Combinations

Foracort (budesonide/formoterol) and Dulera (mometasone/formoterol) are both effective ICS/LABA combination inhalers that can be considered therapeutically equivalent for asthma management, though they differ in their specific corticosteroid component while sharing the same long-acting bronchodilator (formoterol).

Key Similarities

Both combinations follow the same therapeutic principle endorsed by current asthma guidelines: combining an inhaled corticosteroid with a long-acting beta-agonist (LABA) is the preferred treatment for moderate-to-severe persistent asthma in patients ≥12 years old 1, 2. The 2020 NAEPP guidelines specifically recommend ICS-LABA combinations over ICS monotherapy for uncontrolled persistent asthma 2.

Shared Formoterol Component

  • Both contain formoterol fumarate 5 mcg per actuation 3
  • Formoterol provides rapid-onset bronchodilation lasting 12 hours 3
  • Both demonstrate similar cardiovascular safety profiles with no clinically significant effects on heart rate, potassium, or glucose at therapeutic doses 3

Key Differences

Corticosteroid Potency

The primary distinction lies in the ICS component:

Mometasone furoate (Dulera):

  • Exhibits 12-fold greater glucocorticoid receptor binding affinity than dexamethasone
  • 5-fold greater affinity than budesonide 3
  • May cause greater HPA axis suppression at higher doses (22-29% reduction in 24-hour cortisol AUC with 200 mcg twice daily) 3

Budesonide (Foracort):

  • Well-established safety profile with extensive clinical experience
  • Lower glucocorticoid receptor binding affinity than mometasone 3
  • Potentially less systemic absorption

Clinical Efficacy Evidence

For Dulera (mometasone/formoterol):

  • Demonstrated 50% reduction in asthma deteriorations versus placebo in patients uncontrolled on medium-dose ICS 4
  • Superior lung function improvement compared to mometasone alone 4
  • Well-tolerated in trials up to 52 weeks 4, 5

For Foracort (budesonide/formoterol):

  • Meta-analysis showed 50% reduction in treatment failures versus budesonide alone 6
  • 51% reduction in oral steroid use compared to ICS monotherapy 6
  • Extensive evidence supporting MART (Maintenance and Reliever Therapy) regimen, which Dulera does not have FDA approval for 7, 8
  • Recent 2026 systematic review confirms significant reduction in severe exacerbations (HR 0.57-0.62) 7

Practical Considerations

Dosing Equivalence

While not directly studied head-to-head, approximate equivalence:

  • Dulera 100/5 mcg ≈ Foracort 160/4.5 mcg (low-medium dose)
  • Dulera 200/5 mcg ≈ Foracort 320/9 mcg (medium-high dose)

MART Capability

Critical distinction: Budesonide/formoterol has robust evidence and guideline support for use as both maintenance and reliever therapy (MART regimen) 2, 7, 8. This approach reduces severe exacerbations by 38-43% compared to traditional SABA reliever therapy 7. Dulera is NOT FDA-approved for this indication and should only be used as scheduled maintenance therapy with separate SABA for rescue 3.

Age Considerations

  • Dulera: Approved for ages ≥5 years (50/5 mcg for ages 5-11; 100/5 or 200/5 for ≥12 years) 3
  • Foracort: Extensive pediatric data supporting use in children 8

Safety Profile

Both combinations demonstrate comparable safety:

  • Similar rates of dysphonia, oral candidiasis, and cough 4, 9, 10
  • No increased cardiovascular risk at therapeutic doses 3, 9
  • Mometasone shows greater HPA axis suppression potential at higher doses 3
  • Recent 2026 pharmacovigilance data for budesonide/formoterol identified expected respiratory ADEs plus some unexpected signals (visual impairment, memory issues) requiring monitoring 10

Clinical Algorithm for Selection

Choose budesonide/formoterol (Foracort) if:

  • Patient would benefit from MART regimen (moderate-to-severe asthma with frequent exacerbations)
  • Concern about systemic corticosteroid effects
  • Cost considerations favor budesonide formulations
  • Extensive real-world experience desired

Choose mometasone/formoterol (Dulera) if:

  • Patient requires scheduled maintenance therapy only
  • Previous inadequate response to budesonide-based regimens
  • Once-daily dosing preference (though both are twice-daily)
  • Patient already stable on mometasone monotherapy

Common Pitfalls

  1. Do not use Dulera as reliever therapy - it lacks evidence and FDA approval for MART; use only as scheduled maintenance 3
  2. Monitor for HPA axis suppression with higher doses of mometasone (≥200 mcg twice daily), especially in children 3
  3. Ensure proper inhaler technique - both are MDIs requiring coordination; consider spacer use
  4. Do not abruptly discontinue - taper if switching between products to avoid adrenal insufficiency
  5. Rinse mouth after use to reduce oral candidiasis risk with both products

Both inhalers represent guideline-concordant therapy for moderate-to-severe asthma, with the choice primarily driven by whether MART capability is desired (favoring budesonide/formoterol) versus scheduled maintenance-only therapy (where either is appropriate).

References

5
Research

Mometasone furoate/formoterol in the treatment of persistent asthma.

Expert review of respiratory medicine, 2011

Related Questions

Should I rinse my mouth with water and spit after using Symbicort (budesonide/formoterol) inhaler?
What is Symbicort (budesonide/formoterol)?
Is Symbicort (budesonide/formoterol) an appropriate option for an adult with mild persistent asthma who has no recent severe exacerbations, no hypersensitivity to budesonide or formoterol, no cardiac arrhythmias, is not pregnant, and has inadequate symptom control despite low‑dose inhaled corticosteroid therapy?
How should a 72-year-old atopic man with a persistent asthma exacerbation lasting more than one month despite intermittent budesonide (inhaled corticosteroid) / formoterol (long‑acting β2‑agonist) therapy be managed?
What is the appropriate dosing of Foracort 100 (budesonide 100 µg/formoterol 6 µg) for a 10‑year‑old child weighing 24 kg with asthma?
Do over-the-counter omega‑3 (fish oil) supplements provide any health benefits?
What is the appropriate management of iron deficiency anemia caused by blood loss?
In a small group weight‑management class led by an adult‑gerontology primary‑care nurse practitioner, which patient is most likely to have the greatest difficulty implementing the counseling: a personable patient living with their children, a worried patient with an adult child serving in military conflict, an extroverted patient raising grandchildren, or an introverted patient who rarely speaks in the group?
Can risperidone cause depressive mood?
Are there any clinical studies evaluating AlkaMelt or the combination of berberine and ginger?
What is the significance of a blood urea nitrogen of 33 mg/dL and how should it be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.